Results of Three-Dimensional Conformal Radiation Therapy for the Treatment of a Solitary Sternal Relapse of Breast Cancer

흉골에 단독 전이된 유방암의 삼차원 입체조형 방사선 치료 성적

  • Kim, Hae-Young (Departments of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Huh, Seung-Jae (Departments of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Park, Won (Departments of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Choi, Do-Ho (Departments of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Kang, Min-Kyu (Departments of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Yang, Jung-Hyun (Departments of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Nam, Seok-Jin (Departments of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Im, Young-Hyuck (Departments of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • 김해영 (성균관대학교 의과대학 삼성서울병원 방사선종양학교실) ;
  • 허승재 (성균관대학교 의과대학 삼성서울병원 방사선종양학교실) ;
  • 박원 (성균관대학교 의과대학 삼성서울병원 방사선종양학교실) ;
  • 최두호 (성균관대학교 의과대학 삼성서울병원 방사선종양학교실) ;
  • 강민규 (성균관대학교 의과대학 삼성서울병원 방사선종양학교실) ;
  • 양정현 (성균관대학교 의과대학 삼성서울병원 외과학교실) ;
  • 남석진 (성균관대학교 의과대학 삼성서울병원 외과학교실) ;
  • 임영혁 (성균관대학교 의과대학 삼성서울병원 내과학교실)
  • Published : 2008.06.30

Abstract

Purpose: To evaluate the response and survival rate after three-dimensional conformal radiation therapy(3D-CRT) of patients with a solitary sternal relapse of breast cancer. Materials and Methods: Seventeen patients between May 1996 and June 2005 were evaluated with the salvage 3D-CRT treatment of a solitary sternal relapse of breast cancer. The treatment fields included the gross tumor volume with 2 cm margins. The total radiation dose was $35.0{\sim}61.5$ Gy(biologic effective dose of $43.7{\sim}76.9Gy_{10}$ using an $\alpha/\beta$ ratio of 10 Gy), with a daily dose of $1.8{\sim}3.0$ Gy. The tumor response was evaluated by the change in maximum tumor size via follow up CT scans $1{\sim}3$ months after the completion of treatment. Results: An objective tumor response was achieved in all patients, with a complete response in 5 patients and a partial response in 12 patients. The 5-year overall survival rate was 51.9%(median survival time: 27 months), and the most important factor affecting overall survival was the disease-free interval(interval from primary surgery of breast cancer to the development of sternal metastasis): The 5-year overall survival rate was 61.8% for patients with a disease-free interval ${\geq}12$ months and 0.0% for patients with disease-free interval <12 months(p=0.03). Conclusion: The response to 3D-CRT was good in patients with solitary sternal relapse of breast cancer. Particularly, patients with long disease-free interval from primary surgery survived significantly longer than patients with short disease-free interval from primary surgery.

목적: 본 연구는 흉골에 단독 전이된 유방암 환자들에 대하여 삼차원 입체조형 방사선요법을 적용한 치료 성적에 대해 알아보고자 하였다. 대상 및 방법: 1996년 5월부터 2005년 6월까지 유방암의 흉골 단독 전이 병변에 대해 구제적 방사선 치료를 받은 17명의 환자를 분석하였다. 방사선 치료 범위는 종양으로부터 2 cm 여유를 두었으며 치료 선량은 하루 $1.8{\sim}3$ Gy로 총 $35.0{\sim}61.5$ Gy이었다. 종양 반응은 방사선 치료 종료 후 $1{\sim}3$개월에 시행한 컴퓨터 전산화 단층촬영영상으로 평가하였다. 결과: 전체 환자 중, 5명이 완전반응을, 12명이 부분반응을 보여, 모든 환자들이 방사선 치료에 객관적 반응을 보였다. 환자들의 5년 생존율은 51.9%, 중앙 생존기간은 27개월이었다. 환자들의 생존율은 유방암의 초기 수술일로부터 흉골 전이가 발견되기까지의 무병 생존기간에 영향을 받았는데, 무병 생존기간이 12개월 이상인 환자들의 5년 생존율은 61.8%이었던 반면, 무병 생존기간이 12개월 미만인 환자들의 5년 생존율은 0.0%였다(p=0.03). 결론: 흉골에 단독 전이된 유방암 환자들의 방사선 치료에 대한 반응은 우수하였다. 유방암의 초기 수술로부터 흉골재발이 발생하기까지의 무병 생존기간이 긴 환자에서 방사선 치료 후 생존율이 양호한 것으로 나타났다.

Keywords

References

  1. Elder EE, Kennedy CW, Gluch L, et al. Patterns of breast cancer relapse. Eur J Surg Oncol 2006;32:922-927 https://doi.org/10.1016/j.ejso.2006.06.001
  2. Koizumi M, Yoshimoto M, Kasumi F, Ogata E. Comparison between solitary and multiple skeletal metastatic lesions of breast cancer patients. Ann Oncol 2003;14:1234-1240 https://doi.org/10.1093/annonc/mdg348
  3. Boxer DI, Todd CE, Coleman R, Fogelman I. Bone secondaries in breast cancer: the solitary metastasis. J Nucl Med 1989;30:1318-1320
  4. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the Europeanorganization forresearch and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341-1346 https://doi.org/10.1016/0360-3016(95)00060-C
  5. Singletary SE, Walsh G, Vauthey JN, et al. A role for curative surgery in the treatment of selected patients with metastatic breast cancer. Oncologist 2003;8:241-251 https://doi.org/10.1634/theoncologist.8-3-241
  6. Batson OV. The function of the vertebral veins and their role in the spread of metastases. Clin Orthop Relat Res 1995; 312:4-9
  7. Kwai AH, Stomper PC, Kaplan WD. Clinical significance of isolated scintigraphic sternal lesions in patients with breast cancer. J Nucl Med 1988;29:324-328
  8. Noguchi S, Miyauchi K, Nishizawa Y, Imaoka S, Koyama H, Iwanaga T. Results of surgical treatment for sternal metastasis of breast cancer. Cancer 1988;62:1397-1401 https://doi.org/10.1002/1097-0142(19881001)62:7<1397::AID-CNCR2820620726>3.0.CO;2-2
  9. Haraguchi S, Hioki M, Hisayoshi T, et al. Resection of sternal tumors and reconstruction of the thorax: a review of 15 patients. Surg Today 2006;36:225-229 https://doi.org/10.1007/s00595-005-3134-0
  10. Soysal O, Walsh GL, Nesbitt JC, McMurtrey MJ, Roth JA, Putnam JB Jr. Resection of sternal tumors: extent, reconstruction, and survival. Ann Thorac Surg 1995;60: 1353-1358 https://doi.org/10.1016/0003-4975(95)00641-W
  11. Carbognani P, Vagliasindi A, Costa P, et al. Surgical treatment of primary and metastatic sternal tumours. J Cardiovasc Surg (Torino) 2001;42:411-414
  12. Mansour KA, Anderson TM, Hester TR. Sternal resection and reconstruction. Ann Thorac Surg 1993;55:838-842 https://doi.org/10.1016/0003-4975(93)90102-N
  13. Grosu AL, Molls M, Zimmermann FB, et al. Highprecision radiation therapy with integrated biological imaging and tumor monitoring: evolution of the Munich concept and future research options. Strahlenther Onkol 2006;182:361-368 https://doi.org/10.1007/s00066-006-1504-1
  14. Suit HD, Miralbell R. Potential impact of improvements in radiation therapy on quality of life and survival. Int J Radiat Oncol Biol Phys 1989;16:891-895 https://doi.org/10.1016/0360-3016(89)90883-3
  15. Chung EJ, Suh CO, Park W, Lee HD, Lee KS, Kim GE. Parasternal recurrence after curative resection of breast cancer. J Korean Cancer Assoc 1998;30:253-261
  16. Semrau S, Gerber B, Reimer T, Klautke G, Fietkau R. Concurrent radiotherapy and taxane chemotherapy in patients with locoregional recurrence of breast cancer. A retrospective analysis. Strahlenther Onkol 2006;182:596-603 https://doi.org/10.1007/s00066-006-1549-1
  17. Rutz HP, Lomax AJ. Donut-shaped high-dose configuration for proton beam radiation therapy. Strahlenther Onkol 2005;181: 49-53 https://doi.org/10.1007/s00066-005-1280-3
  18. Karger CP, Jakel O. Current status and new developments in ion therapy. Strahlenther Onkol 2007;183:295-300 https://doi.org/10.1007/s00066-007-1645-x